Specialists at rare disease drug launches, Cambridge BioMarketing was snapped up by an expansion-minded healthcare services firm, Ireland's UDG.
Celgene will pay $280 million to settle an off-label marketing case it has fought for years; it's among the larger recent whistleblower deals.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
Brand agency Owen Health charted its own version of the well-known scientific table using pharma marketing elements instead of chemical ones.
What should you eat when you have cancer? Savor Health is working with drugmakers on nutrition programs that aim to answer that very question.
The immunotherapy mystery deepens. Merck’s Keytruda missed its goal in a head and neck cancer trial—one its Bristol-Myers rival Opdivo met last year.
A new report sets out pharma's U.S. pricing problem, and topping it off is the growing cost of access: $1,100 per capita.
GlaxoSmithKline hopes to get its new Benlysta formula under lupus patients’ skin—literally.
Cyndi Lauper is back to star in another round of Novartis’ Cosentyx marketing. The '80s pop icon appears with two real-life patients in a new TV spot.
Pharma's big on disease awareness, but Allergan is going really big with its latest push: It’s aiming for a whole month dedicated to uterine fibroids.
Merck & Co. nabbed tentative FDA approval for its Lantus copy, Lusduna, which would be the second follow-on challenger to the Sanofi blockbuster.